Retatrutide

Retatrutide is a synthetic triple GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptor agonist — the most advanced metabolic peptide compound currently available for research. By simultaneously activating three distinct incretin and metabolic receptors, Retatrutide delivers a uniquely powerful and broad mechanism that goes far beyond conventional single- or dual-agonist peptides, enabling unprecedented investigation of energy homeostasis, glucose regulation, and lipid metabolism pathways.

Triple receptor agonist — simultaneous GLP-1, GIP & Glucagon activation for unmatched research scope
Most potent metabolic peptide — studied for up to 24% body weight reduction in clinical research models
Comprehensive metabolic coverage — energy balance, insulin secretion & hepatic glucose output investigated simultaneously
≥99% purity — HPLC-verified, every batch
Flexible dosing — RT5, RT10 & RT20, matched to your protocol

Main Benefits:

• Triple incretin receptor activation — GLP-1, GIP & Glucagon pathways studied simultaneously
• Most potent weight reduction candidate in current peptide research — up to 24% body weight reduction
• Investigated for superior insulin secretion and beta-cell function vs. dual agonists
• Hepatic glucose output modulation — glucagon receptor pathway for liver metabolism research
• Lyophilized format — stable, consistent reconstitution and extended shelf life

For Research Use Only.